Disease Areas
Diabetes
Obesity
Cardiovascular Disease (CVD)
Chronic Kidney Disease (CKD)
Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Neurodegenerative Diseases
Haemophilia
Sickle Cell Disease
Primary Hyperoxaluria
Growth Hormone Disorders
Hormone Replacement Therapy
Congresses
Scientific Publications
IME
Search Science Hub
Register
Login
My Account
Welcome to Novo Nordisk Science Hub
Are you a healthcare professional?
No
Yes
Congresses
CTAD 2025
From real-world data to clinical trials: The case for investigating semaglutide in Alzheimer’s disease
CTAD 2025
CTAD 2025
1 - 4 December 2025
From real-world data to clinical trials: The case for investigating semaglutide in Alzheimer’s disease
Authors
:
Peter Johannsen
1
Affiliations
View Details
Hide Details
{{ getPageNum(PDFPage) }}
Share
Copy link
{{pageUrl}}
Keywords
Alzheimer's Disease
Congress oral presentation
GLP-1 RA
Semaglutide (oral)
PHASE 3 (RCT)